<SUBMISSION>
<ACCESSION-NUMBER>0000950133-07-002897
<TYPE>8-K/A
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20070705
<ITEMS>1.01
<ITEMS>9.01
<FILING-DATE>20070709
<DATE-OF-FILING-DATE-CHANGE>20070709
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NOVAVAX INC
<CIK>0001000694
<ASSIGNED-SIC>2836
<IRS-NUMBER>222816046
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K/A
<ACT>34
<FILE-NUMBER>000-26770
<FILM-NUMBER>07969894
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
<PHONE>4849131200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>w36913a1e8vkza.htm
<DESCRIPTION>8-K/A
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vkza</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM
8-K/A</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported) July&nbsp;5, 2007</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B><FONT style="border-bottom: 1px solid #000000">NOVAVAX, INC.</FONT></B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of Registrant as specified in its charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-26770</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>22-2816046</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top" nowrap><B>(State or other jurisdiction of incorporation or</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Commission File Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(I.R.S. Employer Identification No.)</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>organization)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>9920 Belward Campus Drive</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Rockville, Maryland</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>20850</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>(Address of principal executive offices)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Zip Code)</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Registrant&#146;s telephone number, including area code:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(240)&nbsp;268-2000</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(Former name or former address, if changed since last report.)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant<BR>
under any of the following provisions (see General Instruction A.2. below):</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</B>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On July&nbsp;5, 2007, Novavax, Inc. (the &#147;Company&#148;) entered into a License Agreement with Wyeth Holdings
Corporation, a subsidiary of Wyeth (&#147;Wyeth&#148;). The license is a non-exclusive, worldwide license to
a family of patent applications covering virus-like particle (VLP)&nbsp;technology for use in human
vaccines in certain fields of use. The agreement provides for an upfront payment, annual license
fees, milestone payments and royalties on any product sales. Payments
under the agreement to Wyeth could
aggregate $5&nbsp;million through the end of 2008. The agreement will remain effective as long as at
least one claim of the licensed patent rights cover the manufacture, sale or use of any product;
unless terminated sooner at Novavax&#146;s option or by Wyeth for an uncured breach by Novavax.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company issued a press release announcing the execution of the agreement with Wyeth on July&nbsp;9,
2007. A copy of the release is furnished with this report as Exhibit&nbsp;99.1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Exhibits
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Exhibits</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Press Release issued by Novavax, Inc. dated July&nbsp;9, 2007</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Novavax, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">(Registrant)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July&nbsp;9, 2007
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Len Stigliano
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Len Stigliano</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President, Chief Financial Officer and
Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>w36913a1exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="w36913a1w3691300.gif" alt="(NOVAVAX LOGO)">
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Contact:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tricia Richardson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Novavax, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">240-268-2031</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Novavax Licenses Wyeth&#146;s Virus-Like Particle Technology</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ROCKVILLE, MD (July&nbsp;9, 2007) &#150; Novavax, Inc. (Nasdaq: NVAX) announced today that is has signed
a non-exclusive, worldwide license agreement with Wyeth Holdings
Corporation, a subsidiary of Wyeth (NYSE: WYE), to obtain rights to a
family of patent
applications covering virus-like particle (VLP)&nbsp;technology for use in human vaccines in certain
fields of use. The agreement provides for an upfront payment, annual license fees, milestone
payments and royalties on any product sales. Payments under the
agreement to Wyeth could aggregate $5
million through the end of 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax is developing pandemic and seasonal influenza vaccines based upon the VLP technology. VLPs
mimic the three-dimensional structure of a virus but do not contain genetic material. Therefore,
they cannot replicate and are believed to be incapable of causing infection or disease. Because
VLPs maintain functional properties of two influenza surface proteins, hemagglutinin and
neuraminidase, they have been shown to activate multiple responses in the immune system. The
licensed patent application supplements Novavax&#146;s extensive patent portfolio in the VLP field.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are delighted to have completed this license agreement with Wyeth and see this license as
another important step in building a strong intellectual property position for our influenza
vaccine programs,&#148; stated Rahul Singhvi, President and Chief Executive Officer of <BR>Novavax, Inc.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Novavax</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax Inc. is committed to leading the global fight against infectious disease by creating novel,
highly potent vaccines that are safer and more effective than current preventive options. Using the
company&#146;s proprietary virus-like particle (VLP)&nbsp;and Novasome<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> adjuvant technologies, Novavax is
developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral
diseases. Novavax&#146;s particulate vaccines closely match disease-causing viruses while lacking the
genetic material to cause disease, which provides potential for greater immune protection at lower
doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid
mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward-Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Statements herein relating to future financial or business performance, conditions or strategies
and other financial and business matters, including expectations regarding product sales, operating
expenses, and clinical developments are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements
are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that
may cause actual results to differ materially from the results discussed in the forward-looking
statements or historical experience include risks and uncertainties, including the failure by
Novavax to secure and maintain relationships with collaborators; risks relating to the early stage
of Novavax&#146;s product candidates under development; uncertainties relating to clinical trials; risks
relating to the commercialization, if any, of Novavax&#146;s proposed product candidates; dependence on
the efforts of third parties; dependence on intellectual property; competition for clinical
resources and patient enrollment from drug candidates in development by other companies with
greater resources and visibility, and risks that we may lack the financial resources and access to
capital to fund our operations. Further information on the factors and risks that could affect
Novavax&#146;s business, financial conditions and results of operations, is contained in Novavax&#146;s
filings with the U.S. Securities and Exchange Commission, which are available at
http://www.sec.gov. These forward-looking statements speak only as of the date of this press
release, and Novavax assumes no duty to update forward-looking statements.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>w36913a1w3691300.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w36913a1w3691300.gif
M1TE&.#EA)@$N`.8``)*LQK+'V/G]_L;8YAE*>BQ7A(:ANQ1-A,3-VB=/>11-
MBOWZ^?WZ_>/M\_G]^?KY^3ACCJ6[T111A+K0XOW]]1M,@_7]_F6)J4-DA^SZ
M_D%HD_WZ]=[L\E5VF=;BZ1I.BOGZ_/S\_.OU^Q11D1I1BOSY[/3Z]!51B?/U
M^PQ2BOS\__K^]1I0A7R9M0Y-AOGY]?S]^N/R^_OV]%%ZHA%0B?7Y^?3Z_19.
MD/#Z_O[\\190C?[\_/GW^_WY\?[\^/O\^.?I[O[]^O#]_A%1C4ERFO[[__;]
M^<SC]MOR_-'E\^SQ]6)ZE':1JEV"JO#X^FJ"H?S^^`Y3DAE/?OO^_,S>Z_3U
M]'&,J/CX\/O^_M/B^/S^^OK]\>;P]]SF\6V4M_[^^F:*L=OL^!M%<O/\^7R?
MPM;J\Q!*>_[^_59RC__^]E!KB^SY]^;W_!1(@1)3B#9HG1=4B%Y]GQ%4CA<_
M;AE5CSE>A7>2LAQ'?4ED@`].D11(B$QNF`U3@?W]_?[^_O___R'Y!```````
M+``````F`2X```?_@`B"@X03`PA5/0L+4P)"`EB16#(]5P,3A0$(6R4;6%-?
M/FDR00L,*A17#PP[70$M<1H%)`JUM3H%$&I,$1XV`BH\"S)C8SX]-2!G($":
MA(14**<A4U@J144^?7U!.P(",!LY&TK/"!.8"#PJ(3!0[U`P554P0.;/5&,O
M:6<[*M\J%FQP4,;9/0\P9&SP(<#"%!\^5$P)P8`!%`<A=NPP8>^>(!`"'+SH
M5F2'#Q0@'MA+]PR3AQPY&CZ",JXCNGL3G)0HD6,!-I-I=A39T*GC/4T@3'K#
MXL?/GSM0HTH5(R8!@#%I%HF:HJ61@#-!@*`1`Y6`60)XG"Q0<:8:4Q\;_W8L
M$B)D`(`.":A64&!&@@0W;ERX@0-'P@$"53&TF"#"@@^N:=)H>?>"2MZS40G,
M*8``1`@C($"HT+AC6Y`@#4,$Z=$'P)T*;:"V.7!`#!,9#/S`>P=C!P@13^:0
ME7J'ZIT]5&P$"W(1V`(?-0((;T,=LQ@('%Y`;/@PHH`0$*=4R1C"29,[!&`?
M,",E?020#GYTT^CCC(TN<8A+C1TG`PH_#1FQ`@53<(`'5=3=T8998B`&`!LU
M++!#4RILTX<**CC!1@=F4>?A@E:A`%X0D33UARTHVN+&8410,441#(CCP#N-
MA,8%&@3<D$<M!TB!APT^?5$-)(LL\``/5!B@0?\"%1Q`PPDC#/'!![?<<,,'
M)'R0QP@ZT"9%'78$H$1*&U!`01H;O+#&$U(H0`,-MY`@01L&V."$":*%H%H1
MII$H``BE<-$$E3?HH8`.0RA00`"YA?`#;S#TL0`(`<R2XA!/GB"!%&3$H,)"
M4*Q@1$`[O&#@`7FD^N0!5[(0`#@+?-/=-S#`U0<(,#P`@@<0*&`E#7*D0,,!
M$'@0VF0P9+1#$&F8$$$".HPPP@TZG&#+L"P,8$,.DZVP@@,-35`'"WE<&:6F
M+)@!00`6['`*AO"&((`(`$@A`0V86CM$%&:TP`$($`4!PQ0FGF#PP0B[X((.
M++20`0A%+)##"C3^*4#_#!VT8>65'_@(I$EG8`')#KJ*$``&4-$2)9Q=LO#!
M`2X<H`,)),BL@`M#<$E"509D(<`+9F[Q0PT61%"`#O@.4>T)-:,1QA@K@,!`
M.SZ<`A:)6#S0!Q8!U$&""W2P0)L+9L31!0]^O.`.#)%*ZL039@2;*)5##`&8
M&U)`,`$69H;JP&A]$&V`%%$4[A<<).@@@14X8`&#R'U`)/(/,*G@AZ,6`%!!
MEDVZ(<=A=C@!PA0__,"VLA1P<8$9=4<YA%_6_F6&%R+DX(.9%&@!P[P12`'G
M!^<><,)A2Y0AV@\A7%,$.Q:(*T7=0YS``@LTN$!$&$9HYP/;9YA(V_?@2T''
M_YL')$`%#I(*"457WPB`!!%N5/!!!16PX*-:(_8QT0,H-,"$&)NKQ0U<H(`#
MU(\P?DE@`FEV`ATH8`1ZR-(<U(```5!N"PZP@`5B,`.9C6!8!R!!&Q05`2&L
MH"+@H0`#^J`%'V#M`5BP0`L2(`4X]$@*/1)#!"R@IS,\RG3)`P$"Q$"'/"3J
M`"PHX/=B)H86.*$*/GC'W_PP*2?PR@5OX@-[Q":!`I3!`C^`1.1\(#*:Y`!&
M(7!`!C@DOP(0P`R'2<``!."',YPA'LE*GK,*<$28D4T*]),"'^`@A@&,XSD"
M\\$+JB`$`]!P+R`D`0WL9P41"``*/G#7*4`0`S6(`?]G0W"!%-I#``TDH0:X
M@\%DM%`PA+GR98:IP!/80+H=,,4/D6C(^U(PO>D-#P,9:`A$-B`A'G#!"DS2
M@3)G]H$VS.\.*2A<"E+@@A3((0J\#.$!IJ2#C54``W,LP0HT*``&:.X$<JC;
M\!0PA`K8P80HA`B?H)"&+V!!3P)@@P8(\)?!2(`]!?"``+:QMA^<05<-L((8
M%)`J!61I!%/ZP`T.U08-3,!JU;C<`GZ`!1%X@751X(-?G)0",01`"'UXP$"#
M0,9+P@1&(*@!%>HWI0K4,#8=&-4.VO$.W85FC5H:@?P4(`<7L$!^+&A@!:Q0
M@XI@*'(YH("I_G>"/,A!!X7_&8*P$A``&_Q@(:8`@1(`0``X1%-82#Q``2:`
ME1S4,Q)3Z)Y3EDG79=Y@I!^PBA&("8FF7,Y]1.##"=3Y.0P(X0<.6,`79+``
M8]IA#@>(PM(,=JA#-;,"=,A%`0IPU`\4<4LW8.!@==`&#$R`:!KL0PZHL`<"
M'&`$2ARL`NJ`!!.XJS0P*,)DZNF'T*`@``1@0;2D-8(3F,$`GNF#.][Q`S^@
M0`7/$N[*Z.""**3*B(@Z`0&:H!R_^D&Y%!/`$0CP0"SZZ@8I,,,%.!""*O1)
M9+7R`8S\X`0#Z(&X48)H`7;X`-+`X(=8^.T=2#`"%\!!,-.4`W'320<"#``$
M-B"G_Z06`8(N@"&R41A"CR10-P+480(V>(`/9,`#(3PKA/AR@1S<T,4=CF$*
M0X+$+9T2T1I'-`^T\=4WR_``&4#"CF=82PP"FU2#=2DM49703FT`@`0D44HD
M.)@(69``#;0``(88P"4BT((ET$$/-X`M"7SI!ATT>`8<D!4,<K`&`(@AB?-K
M$IP(P-:XP$NW].1''T(@`BL@\0/*-!@+"C``QK(-'LU5`1">$-P3N$%3-2P`
MOL@G`3B8H0!4^(H66+D-*/R``1E`PQUN,+QMWH`&$O@P>$+`#3_%5R,,Z,(>
M\A!H*-W@#AWH@G;FL]QD`.$\24V!&_@@A0(41@[(-M@_6__`!9!,P4+5X`$(
MJ+!/!9Q@E+&T'YI!,`P;#`!'1V5!E"V=``.PP0)CT*`D+&0BFKG[W9)<YP#%
M```ER,`A7\CW`D*`,:/2]0`8P,$&H."'G0J@#'4X0`%=]H&#':8.!C@?#FP0
MFI@*P`8-B,`^0SAF<<],#W0P0P1LP-.+6(;A]#N`L`A@!2?TP`?)&\UN^;%3
M#]1A!$4^F!F:$(,2;`\>6@B!'X)@M)H-]@1M2,`,6E"``M(OJ;4Q0`W@X0<5
MX"H(#&!R`@X@!\/4XDU6X3:K(_6)*=#'70%(0!1"^Q>(WL$``EA()HO`'"@8
M@0=I#YL$@B6!!(`!#!5PM)3$-@+_""!@SP+11@R_T(,?1,!KRKY7!6C@!GJ+
M0%XBN``!:$&")AW@GU8H@PF@X)4I]&9Y?6CEP21@L$G"R19R@,.B9."`R<1C
M`_PF@@*$J\R)`C,$6``4)\E@!F"=0'X--Q@!,'`$(>`)8@R0$$RQD`$D(#/P
M1KY2><$),`<XH`9">$("RK5[E6LXH&;*XP[@\84@A``$;B9U/P$CA0EDP.?+
MC4<(>(`"-"1@2G2@-%36"WM`/Q7P&LI$950P(!3P7<K"`"C@`7N@<BR616Y`
M`$M@;WDD+Q@A%#ZP`#5@!7<@62S0=A6@`0,0`A2P$$+1!Z7S`TZP!'>@!\&6
M`E\2`!-0_P"LIP/S0P)1H`=V@`*+H`AA-`4OD`-74`,1T"2"@2D?L"\#."]-
M!@=YX`(G``=TT"5$D!UF\@)T]&HEXA174BUN0#UYD%G=I`#SDS-M<`$-T`E3
M8`%&0`&`I0"L9V0`AP.EL0`]8`(#\`:*<R^3=&`Z8`:F-08/$`3>M8A^<'>+
M1@`)IF`050%U`P!.T`??`!)I5S@Z0#\DH&!Z$`&DXRTG1`%0``PPMT858"4W
M-`('H`$QD$E]8$>X)!</D';34S_3=`![P`%70`9WP%!(5&0LP`1"\`#[Q@X:
M$1`U8`!PY'&:\C+K(@.V@PU84!%!@`T"0&TW`!B%,3QB8`=*\/\"#C`%[/`/
MT<<#")`>3Q<%(W`'E:0$1&`O!P!F-\,';S``"X")_[5IFY92,I0`$@`V2'0"
M-/`!8H`&5$`%&-`&7'(`?)`"$&1X#O`MC,B(?R!:TF-<3>`%MM"#"E`!5J%(
M7A%&[_-Y!],E`8=;)3`&`-`&KR.(+$`':LA50E`%R'.1?A4?(3``&N`Y;D`#
MTQ*2F-(!,5`%P0<2,8`&Z#0$TT,";C`$;;`'./`#6_`MV;`[D3,%`Y``8'8#
M]L-A!0``0D`!^RA75&1,:"`%63(]<D`#4C!R/S``$,`"Q95S+"`&R4%,I[",
M,N!M$"`%O"<]+R,%3-`'%`!S18`%)<'_4MY@`!4P`H!A&$AD/B#0`\ER(<I3
M!5VP!,[D2U%P`HL"`K]E+R<003I@A01P`4)0`P)S!EKP!5VQ?R#@/W,`!TI3
M/\-S@#-`!&7U0#1@36HU`2#P`NNCD][U!QNI3'MA!F`P`%_F=('7>1#0!:3S
M`R``+AB#DGBXDBEU!9F'14[R)B=`!Q]``'O`!F-@!,F"G'[P`!M0`_12?$'9
M0&J(*1\V.A,!`DY`5J/%-`;)`G=`!49PE<_6#J=37V(`9@QD&!IP!`4*`T&0
M>D,W*=&5?)X#<&%`<B+0`D1DA0S$`@3`;(PU#:SV`@\0`RU```BC`X:R?"CP
M`XEI2Z,1!#FP_P,94(`?U'K&U1\/0`$PD(PJ4!%*R%E3,ECMM%X@@03[%#W#
M,S.#=@06L!`#(YLPAHPR%0?/XZ)1=BA=4AC50WGG9XDO\`(_\`7N63!)Q9P5
ML)HV0`:Z63,BU$Q,(`*E\PTA<"/<V4!YB%L_0&WB*8CE264`P!6F`P+N"0(;
M\`5CD`1;]R1M4D!@9P#!9R$UP`5U\#P9QC2?UP8`L`9;D`/_P`[NL(T:<`=8
MPDW79@!"<(0.0`&*Z`<P%P/[1`-D^&AZ!0569QFXR4R)DUD!$!`+(#)30`'>
M]P!=*3PG(%$3U08F)0`,*``3L0,Y@`43,"4+4YYT``=<)0`]P!HPA_\AC14&
M'6`&:A@MH9D`$X`",A`"F2-I7;=-LT$`M+,0P)=O(7&$/F`#28`!4C`EUH8H
M6Q(E=&!T)%!N:_`"$O(`:(F<RNEQ5U(!8G`!*$"N+)H'!XDE!QL!-:!2WZ&G
M=\BGWGD1E1(])0@8!O--""`.I(>HR&D2&[`".9I$U^9*!/`$%H`A[?``#N!(
M<%`XI08'"D`$23`@#)"S.[`!/Y`Y_U<SSG0H$#``<VBLB;D-"^`$$2`&3Y*:
MP5(!N68"%-`'&V`"5K"E/,@".5,!%\`%[4JL%&`"/_`"/-`$4F"%$L4E'W`'
M3R`"*[`%QNH`?;`#%(`#8``\MNIP1JFH/0#_'OX0??!7`"XP`K20*E*`!CBP
ML%.0!'OP`7S`8E/"`G"0+<BX-;`9$EL0#Q<W`'4@/Z'U)K;ZNM;&`G/`;$9;
M!##0L#KYL+PW)3?+`SB0=AC&@X!6`6C``3;P"SL`LBG9IRXH`,\B!QOI:)*W
M!UT`$Z=(H3I)=VE`AX"'-%)@LQT@!*<@*2R%`/YZ31+P`26H*`$P!C^@`A:`
M!8OP`FP`!JA*&P#;!G;`!5]EBHFI)]-6KIB"+]-4;D9P!3EPF2\P`5O'(TX2
M!;,5`)[AMD;P50SP+*SW`7J0,_-3!TE@`GX;$LCX`V6@`6'&IY]'``!@`8D7
M`A)2$3P0`WN`ML65_S0)$`$"(`,^\``P@`,&0`"=F[X-MR)>@!);`V.7M`)>
MX0!8^W_6)CW3<Z3+ZK6^.`[+4XYIZA10W$"TT+L/@`-Q0`"%([D`.P<1T!@2
MJKS=J8=]X'U-%@420&8RTP9QP`76BP78JY-?$!E8\,.I";H((P5[(+X5`@-?
M\`(U\#]TD`*&83`CH+\9\`!^8`$"\`#O1Y=M8+`'T&`38`3/X0XNM&\XX&8<
M-BS410/@]`*=H`(]\`)<L`1[44!_X8[;A0,@`%>/(1`+T`4:L*9M\)8.1``1
M,`84@$$.H"O.6P`GO"(]4@`<X``0(10:\0`J\+LLFBBM=P!JT`!QVPT;(/\`
MJBL!=+"L#4<#W)H<>A()?1`J#2$`/G`%4V`'!#8SHQ3%458!>F,".[$6(4$P
M:?H'."=N!B.5%\`#\3D`&!!9>!LM+*`W4^H#0^8"(:N2;&P$`F``+,#(<BR5
M8(`"4=4(L:J3ZJR($<"B*:`ICF8PQ"($/A$"9\`V?8"+)[W)M<`"#QIWTKH(
M1=`"%9!=U8-T1"`"?*D":5`K[4H%1'``-O1Y;^*I-7`%7R#):7*+C^H7?)!.
MHLDNUA`Y<O$<F4-><%E4"F!I'8`##[`%9\`.+X`#,]#3RL0'=""23!!WNR,`
MRQ,"1U(&1"!)#F6%!V#&%A0I"Q`$#]"A&B.Y2?7_)&;0*;CR#;<#!=:P`U>P
M`FOPAX?2<0P799[*!C_P<LNC`A*:Q0"MO@;C!BEP``4M5?WYO<LT`F?8!E;0
M`(HP9(R\O-Z901BMT4FU(AK6!+6#6.[LGNJ\-25-`WF`TBQFD!H@O@R@GV=@
M*IIGSA+032$TEE.P!3#V`S*``AA0`2MFA4_2!CBL"!A2U%\5`@90&*'[>646
M4`-B'Z6#C"A0@*C&!YV[BWL++XT5,0R1!!"`+U)0GRR6`%G``ROP`W)A`E10
M`-RD`WSP<!/P!<:J07=MH3/I4%]C0Q#`!;?K`-SVW'ZHP<45X,,S!'6``"[\
M#64"!10!$28@!%Y`,]6R_X/34BT?L%8IP0I08)83\L^3]6@X5M!J4P-EH*7+
M1&#G%P%'@C'';=M",#"(-3AP+)@&`V@'X-L3`RX3:B%<O@V1D!%%0%9#D`<N
MHRE_\8HLW0[/)C'1(08J-SS)=P#A:P(#,C0(<`=.$ACH)`$04`85K"<N-#4U
MP`$)9\[;Y!?TB@-;D`9%^`.+H`(`P%E89!AP`'9LI1T"("'[^`,P3@)YT!>E
M77D`@`(/0'+R^9(EV$!\L"!6H`174-=VC8P/T`!$0)ZT,01Q#7?&Z0!8X!LE
M<QZ(,IDL(`=FP`1.0#(6Y'V5_`,FT&;!924O$Y17,E)2H`$<(*Q:X.@][IY_
M\/\!*+LB"M"&9XT\-@"\M2`%5B5*&M``"\`%'>!0_V98`[,`9U`O4[ZF>C`_
MN58FO(X%0/;O0/8=<L$`//U!__H!?C$$!(`&%K`%V[-G/B"J#8`!+,`'-74"
M4>`"!7`$8[`%&X`"(F`'!(!#M($O!&``3C!.WW&CS4TOHW:7@-8&:V4#K_H8
M.6T*'M`!=Z!,ZJMP0<X&H6I!VZ,"/C`&`0`!=R68*'OE77!O,-"H36"'?H$T
M>14!\0$0XKK=2[@EUW8O%34`->!]%LT`?S*DCT>)75<8IXT!*"X#2&P!OV`$
M:_!X#5<N'1.4(6D8J%;L7?!5(L,*HNWMCP;NXFX"N0+_`AE`M\PY!$55&P`0
MP^^>.,L$<$_^$#M@-*'I2\O*,"A8.N`B`*01^J1A`8A:ZC-``ICB,F,F`4(5
M!Q:P@I&20NXZ."EPMBP0!32@P@V_`"B`<"1/&P:9`$?@!.#"#IGT`#*%`000
M:)R3`$\0`R+``])O`RA`_?R7`3_,`FT@F`H7/7+4V1,!`W_C`T80`TV@!Z'+
M`H-A,&O%`%B@!490*7(R]4[9`1Z`H@"Q/$'``_@!"&TZ.B<L$B1B+6Q..!F.
M*#A.*"AE%Q4D$E(L+BXG8DPV"S\P`@(\#S9)&&(?'SHW>A4N*302$@<G-"<$
M`")]"WXJ?7[$Q<;$?Q]N;B=N_P<*;1</(0M!#Q94!2PC(SHTNA5U`V$="B2#
M@P<80C!3/BH#$$,C'RPG)R3?!1$6#E,"%KX('$@0RP,5`I`4\$;C'(E[-RH8
M$/!E0X@0,'SX6"`@20$:(TBPD")GB)D.(M(PL!&!@,@*,!54:"+DQP\M&1=L
MM-%"#`L2)%J1@"/ES0P-1)`26;JGJ88W-(;0D?!!050:GQIL2+-CBK\=7XQ$
MD$)C4"$2"NZ0L;%"!HX6!'`=.$`CCY@(3E[P4*%BQPX8.VH`2/#A'*%[!R!H
M6+R4R)[%:I`NC"+GA`07N"HD2`(B#04?1:9YB&-&CIX/%0[H:$4C!:V8=*0"
M$+)@@_\%+,=R^TFVK-FS:`^*Z*0`A8T=`@KRN(@ZQ,6=%DB(F$.G0QT[=R#(
M*;C1ZEX^&BR\U"0^A:#Y+UHVH)JP_`1=?"=6[[,!Q<?%C#M^&&'SY,"00E*X
M,<0!=5`1`@,XQ%'!:A54I4`"_-A'P6<,^"!`&'6DQ@(+W;G!!Q]F\,')B'GH
MT49J>:08A0L*6$6+%'5,`$(."TQAA!$[+."`!WLHT(U(.N1100<<;/%"%GML
MTN(!$N2QF04^!->7#U#T$4,3;9SFRB`IN"&!&9>-J`=F;<2EPPB4-:,++F(`
M8,,&.6RPP!5"`+`@+1_HP0(=<R0@!1\IY*%`G@K0\D826*3_X8]NQ_#&C#/0
M2,/`#CY0D(,02628QSTT1!'%`05,,$,;AJ6SS@]3+,`##E94<$.+)PPAP3*)
M<?!##SG\``447^@*A:\_P/E`#&3`&BM\K6!`A0T_^,``1H`%`<4:`22@P`E$
M23"$3``<V$4!554UB!Y$)&&$#"%8N@$#/X@0@1CY'/#3!Y:Y08.]S&V;(D-H
MYO'?#3H,T24+";2`0P\A"."``SMLT*X!;72#6G(*U!'`%5-$\)$$@S*IQQ,9
MU"!#$5/ZX``6&K/(X9G><)*+P"D,<4,>-,C[##>%G.`"APH<H`$',LBI8P1U
M'##"-PKHH(`$=0!P@1E1O+K:!W#(_W&`%UR\\,(/%_G1QS"Y.>I;I,$5$40:
M:4PAA`'6VA)K%%B!\0:IU*F3`:H/@"!`!`GH88Y_RW@I!0!.7+&!PS=MC=,H
MM_;P0``0''9"90<$=<<3,3#[Q0X8]:&"M"9P@,$!F$FAK4QQ.,'#NU6IQDT;
M+3!KD:44,``"%1W<,40M,-$[US,MMHC:-S4_,XA,@PS1&P$8#+!!*5YEM($)
M`U2P73TLL]""`Q:T*FLK"K!000`6/+"`[4%46D."%>2A`PMS)6W+,\37;'W/
M,,'_DCT<=L,"`"!X@0QNAP$I6,46("&!&0S`A0'4X00W<,$K*F"/$Q0``#6X
M0A"Z]C7=B/\-4L`I@E\$L@`;("$.<7G&$**P+=14KFX8N-L4_,*#+J#!(2?(
M0V]&<A<!R.`!'20&"*;@ARE,`5T#4(-+'C(Y?)`*0A:H@1;\X!?/]4$C+[``
MV^;R)1J8(P%4:,`3Q%`YHRD'`@-P0+!"\(,MJ,0&`/!)<_`A%`G<@V53LP<S
M[A&\PIB%CRRX@Q5*(8`I["H(<[+`$_1`AP^HA@[5@8`3PI"``Z2`*J<A0`=B
MH,8@]$$`6H!"%B<@A@I\0R15T<.L3L"-PVP(8#H0B4C$UZ!"N")\$.!"#4#@
M`328`9(',%W,VC"#-51A#'RC`TC>IXFY)"``-7A`,8+8*&4\ZC?_TBA"'["`
M!>'\8`P3*-H!&C0$J>3IA>BP&ZIX0(T:1`!,<XF"EWXR`CJTJ0Q"*`4*;"``
M+`@`!`!E0P`*0``*T@LQ)#C`')[0`",X0`L5"H(*L`"#!2P`H![00!O@`*D1
MZ($7`ST`'>Q1S@6*(`0-@X$17@"%*0Q``V:``TA&4`@6M.%W7N2B!/CPN[G\
MY`!M.&@L?U((,%I``"$(P@I`P(`'H``!A*G`"5*@&ID@``!F<(,+ON2>.?!#
M`(@LQ0J@@`4NS(``\.M2,-'RNU;`1`I2`%Y/X>>*>K1"7&T@7`QF(`8Z7&N<
M3)*"LFKP`U0``#G_F=I#2&`Q"X2`&"$`_ULU>P/";&Y3`"JHS1AB8``SG(@%
M`AK4M4I5G1BB"J"5:L`,?J=#37P@"GGX0`'B$`$/*`$%>A.`#:K@`01XH0#M
MJ6!-\4&""=C`!&,M@@\D*H"*,H`!<VK!'5AY@J3UC`A-D,+D<*$+%B#`"`_(
MD184Y@`8V"$U<)#`"/P5S#<LYKWPC6]\$V!'!E7P#G80@0`JM(5=/N`%2B!"
M+-QP20A^C`A_2L%(.%8'()0B!-<P`G(%$`#QP54.79)"!=PKW\5P&+Z*@4#^
M[NJ@#@P`8A_@3E5>)0$(X78,(`B!:EWAABC0(Z%NN,,,!@#$BTC6&,FXAV4,
M>`!I[&";6.A#A?^N\2TPT4`.;C`'"?YSQQ&H`P<+B&P?8/`#"TR`H!_8U%R"
M%`5S$"`!:K`"`"+`9@#8`0T)$(,$Y-!=H,@+*`3P`AL$H*N;^``&V^P#2D6X
M@H&R@,XM4AH)"J`M>3:'!2AQ*$:FH*L7<"!#!W!#22C#M`EDX=.@_G02CA#J
M3Q_A"%18`@%T<8*XNJ<"!:"""ABP@2WH31@AL-.A71"4U22`!!YB1GJEP(0M
M.("I#/CG`VJ0@29PL6H@(=`$DE#J+"1AU*8^=1*H<`2-43"A:+E'`CI0@!NH
M6`%#R`,)I&`%%/#`=M/P,@8((`<ZKT9G!_B`%6*`@U]4D9NXV0VK@RG_!1>8
MX0(RR(V@0P""EL`A!?+<4!/OL<(K,T";@M9/!OCF*EV4Y5IT=&$;1DYR"@:.
M&;_CT`<(``8DV`"E.ED!H+]&<YHWX&F"`A^+W^:I(50@`F,8@Q&T,`4M6*H&
M+1C4VS"<@@4"FE&,"H$/^`:'W66"9WRP`@AX4"D?^/-S,:@#O?-P[AM0>7)=
MBE$.8(#229W/!@'`A9!3?(,#M&`%4V34D?U):2C4H`Q-B`NVO'&/#:78A>6D
M@1EFD`493,IV6'"".X%[B^KVC&-2,``;S">#!2"DG\@H'L$-?H$>*/PB(8A!
M!RX!'KCN%*ZFDX-@,P""8?0!"BM8@1`R`(`"_U2`#[>H'(D_8(OBNP$.'+6C
MD.-SM!$,00QQ0((0J.$7:<V\YC2'NQ@&!9,*P%X3H&T(!,I@A"E\S>A;,($'
MZL"'D9AN&4RCP@)V`/5C?`W"2D"#JS9UUQN8`8P@L`!I`&A\$0068`=2X%>H
M`5?>!U<51``7D`%;\&=!D#Z.<W-@XH!W!0$3X`,_9G^7Y0<9\0!"P'%M4%UF
M,4L-^`Q!40#D\UP[X$EZ8P-*`!<L\`W+814T0`#[``(RX`,[P!<BA`RT@#2D
M<W`O<'H7P0!4D`!Q47RS(@&&<`*?$D/]X`?HEWX9(`0!@`8&)Q>S]$KFQ@W!
MLQW<T`WNX1YF``$&T/\``O`"&P"$?G%]V/<U/"`"2H0:CA1,&Z()E@,`;/`#
MSS51%.``8\`$!,`';C`2]G``!&``3K``'PAU$,9&??`N$7,O8W8"^(4$%@`#
M!*@",(`#`X`!9C`"!V0+X`<4!$,^AN,#6N``.9`&R&0M\]0@B-`"3C`I4/<%
M9\!-5%0--E`&'4``IM,,]09_Q4<#K7`7*+``7R`MO^(Y`-4`2R`&(^`:'R<!
M-*`'XA!-(:`"17!Q1!@59&<5!S<&2D@-.,`$E10?9X(FY80F=F,$*^`U/K`%
M^F@":\`&`^`%$&",VA4K]38_/<4D5-A*!),`!=`!`<`!6G,X\U<$%*EE==C_
M!]\41[=D%3ZB/&Z@`[!V!+1Q/J70!S:0#701!>^S#:!"!1:P`V=0?\:`>I&%
M!!I0`2,@!P;9:A8C!%OF.<)@`3%@!6903KOS#<RGD@00!UT``A()$(48!DU0
M`7I@8ZUP`XPU`9@UB<7P!5,`C`WC`R#@!"U!4BOD*<Y'/$-``A7P!%RP`10P
M5KLR"FT'`@B``1_0&DC)C7E@!G%`!4BU`Q1)?P*7;VY5`6)P`4Z`?5ZS<+;Q
M4F:@<JTP-2E6`7B``PY``5^3$1.R`MQC`0+U!`4@!F:R7E#()/-C!GE`#P0@
M!@F`!A$0!D(`AR\0BT!9D1?Y-11@!)E24/F6&C=0_PL24`%W$`?Y9%$)<QM*
M8`!S@!K<D3]2<`%"``)T2$V-B7VHMS9WX$@,"!.MR00G17/"X``E6$G/T`KR
M$BL^YU4V4"%R`A!0T'`9H@<,TB!B8`4<`%!<20Q$QTTBU#`_\'=U4$H-`DOG
M-A<$(`YOL@6YMRN_$@1^\0`\$$>D(YQPP`DT(`5V$`-3$(<6Z0<:@`'QA0$M
M4`6,:0QI8`$;]Q@=MA@8L`0HH#6#>0;I0R7^8",64`81T`0W&50'.1=F8`;R
MPI`S8`!)D`'^\`"Z\@^E@`5]4006:9T4\`-.T`(B"E\?I@$.&45`&`(6<%0#
M\`17RF$B.@,3(`1*6H?&D/^;7V,$5/`$[X4!<HH!$/"B`Q!CXOD"#M`%5J`!
MBO%>$!"H[K4$70!S<O(/4*`$3(`''A:BD&%<+\``^XF%I(!9.;(`$S(&!J`&
M5]JB(1H!TQF7#:H%T5B!&^$6K>(*<.!9!_!P0R`%!M,#NVE^P]``MGJK#<`!
M#2`#)UH,8FD!:\`!PHJKMRJL0&!1"T"114`,<PB*/:`>`"4"'#`!$6``8-`$
M2?&G,]`$7A`!TQ8#&8`#-5`%+X`>A`0]@`&EO>H'&R`#,J`$PAJO\CJLN'4&
M4-`.7^H`-3"O\MH`N^474?IC;-H'/0`"2I"KQ%H&9<`!3H"G1M0'.\`#/`"O
MNDK_K,,*!-"U`P\`EU0"!48@K&$0!L-ZJS;``Q9%F+JA!4#I.912@2%PL,2*
MJ_)J`RB0([C74D1T!C'(%0S@`%1`!-O))(YD!A!W``F@E28P!@[00=!U/K/&
M`U@0`CVPKG[P7$T%+;Y":SE``18P!E`@)Y."LGRQF13Y7!?E-:!H`V/@!$XP
M!E_ZMC=2`^5G1$84`N8GA!I!'"H0L,:@$SW@>;.F$P*P`&R'$9W'`%-@`N5%
M)3>R`FD`!7SV`Z4``R_`<"$@`]6YIFR:`W_[`BNPM3JQ!6,@!$;``T?6!T;T
M%^9C.^((73_P&1`J'">;5!KA`_]07E40@&SG#EG6%QN`_[(*]S5TBUE\82E;
MFWLK8+SK@K@0EJQ95G0Q:7M^\`5I\`.U26%BYU>GP0(!\ZHQ0KJT6K7/:A\O
M``)'M0%4^T\0YBL+XP!2EP.B.P8K\+<5LES#,+9;-@J%"P(JL'4`%6-+^%P@
M\`#ZR*"_<@8/"QAF2SN0JZ;%X``OT`..,XX6)8HPP$U?*XE8(+\^$(<"L%)Q
MHEP)(P`=_)E;D+G3Q*:C`)\_<#X]JX\4("=V6W0[8`%&0`U?]UP+@Q,0>[)*
M>B`D^4\;\*SG8[=Q`@+\M'90-[9$QZ2E,,`\,`4`A7KSYQ=\\5Q1;,-G<`8=
M]#74"P4F<`8/(`*#,3,KYC>U8/\&1%`&2-5!2;5!/_FP5/M86WP&H#AS%S$*
M_@`#GM0'?1R]7U/'@!:36H9Z-!>P=ZP%9_`#=5A%=UR=UDEIH+B$ADQSDWP1
MY85Z1G3)G/,UB%2ID*RY;!H,6'`&!_(L&'&OYQ/(7/P/@K9PSV6W"Q>PLQQ9
M%S&[D14$@,9-O@AUKTQS7YED]^LU?,$7E'S,VS0%@-Q!6^P#C$QI3F`%<V!N
M-S`"K^)(JPH&8<"_(!"\-">3OEQSX,PH5%M_#DP,`RNP`RO*Z6R=Z<S.%PG/
MYWR=[:S.HSS.("C.XSS/]6=1J,MV7;!Z)$#-Z#DYL!H#X)C/UHG/Z*S/#)W"
MWXS/\_S_SA"=F_*\SA4=SQD]T1C=T/5LSQ;]T!X=T>#,SU"7(W\!`TC\9140
M5*NQ(9T"*@"``UNCT),JD^4LT0Y=TNM*T2.MT3_MT_0,U$/-T?<<U!U=U#G-
MTSMMSDNM<'XQ0E6@17Y"5#_A`I0!*G?Z6/`LTAGMU3_-T$8=TDB]TQ_MSDDM
MU&I]UA?=U#KMUN3\U,?@3QL1!!1P!27``4R@79Y2"'0A06U0+A9@TV`]U(4M
MUS8-TD2]UA_=UB2MU&:=UFR]T8@=UW"M&R;-*%C`NV=3`I<R`$2`U5%04\ND
M`Y<C`G^0VJG=**K=VJ[]VG_`VK`]VZHMV[1=V[8MDZVMV[B-,\^[77^_#77!
MS2C##<[%'3:W/=O(G=RQ;=O)[0=U+!`4(`!"0`4`8```D-W:?=W7#02!```[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
